VRTXNasdaqSEC EDGAREDGAR

VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations·BOSTON, MA·FY end 12/31·CIK 875320

Board of Directors

11 members · 9 independent · FY 2025
DirectorRoleTenureAgeCommitteesIndep.Annual fees
Sangeeta BhatiaDirector9y57TechNCG—
Lloyd CarneyDirector5y64NCGAudit—
Alan GarberDirector7y70NCGTech—
Reshma KewalramaniDirector · CEO4y53———
Michel LagardeDirector1y52Audit—
Jeffrey LeidenChair15y70———
Diana McKenzieDirector4y61AuditComp—
Bruce SachsLead Independent26y66CompNCG—
Jennifer SchneiderDirector0y51Comp—
Nancy ThornberryDirector1y69Tech—
Suketu UpadhyayDirector2y57AuditComp—

Risk-factor diff

10-K Item 1A — YoY changes

Need at least two years of 10-K filings to compute. Will populate once both this year's and last year's 10-Ks have been ingested.

Policies & disclosures

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.